Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1993 1
1997 1
1998 1
1999 1
2005 1
2010 2
2013 1
2014 1
2016 3
2017 1
2018 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
[Thymomas].
Sánchez Heras AB, Pastor Borgoñón M, López Rodríguez A, Montalar Salcedo J. Sánchez Heras AB, et al. Among authors: pastor borgonon m. An Med Interna. 1989 Dec;6(12):651-5. An Med Interna. 1989. PMID: 2491478 Review. Spanish.
E-SHAP for refractory and relapsing lymphoma: influence of patient selection on response rate.
Aparicio Urtasun J, Gómez Codina J, Molins Palau C, Pastor Borgoñón M, Maestu Maiques I, Munárriz Gandia B, Montalar Salcedo J. Aparicio Urtasun J, et al. Among authors: pastor borgonon m. Ann Oncol. 1993 Dec;4(10):896. doi: 10.1093/oxfordjournals.annonc.a058402. Ann Oncol. 1993. PMID: 8117612 Free article. Review. No abstract available.
SEOM clinical guidelines for the treatment of head and neck cancer (2017).
Iglesias Docampo LC, Arrazubi Arrula V, Baste Rotllan N, Carral Maseda A, Cirauqui Cirauqui B, Escobar Y, Lambea Sorrosal JJ, Pastor Borgoñón M, Rueda A, Cruz Hernández JJ. Iglesias Docampo LC, et al. Among authors: pastor borgonon m. Clin Transl Oncol. 2018 Jan;20(1):75-83. doi: 10.1007/s12094-017-1776-1. Epub 2017 Nov 20. Clin Transl Oncol. 2018. PMID: 29159792 Free PMC article.
Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population.
Fernández-Mateos J, Seijas-Tamayo R, Adansa Klain JC, Pastor Borgoñón M, Pérez-Ruiz E, Mesía R, Del Barco E, Salvador Coloma C, Rueda Dominguez A, Caballero Daroqui J, Fernández Ruiz E, Ocana A, González-Sarmiento R, Cruz-Hernández JJ. Fernández-Mateos J, et al. Among authors: pastor borgonon m. Cancers (Basel). 2019 Apr 7;11(4):493. doi: 10.3390/cancers11040493. Cancers (Basel). 2019. PMID: 30959967 Free PMC article.
SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma.
Pastor Borgoñón M, Mesía Nin R, Cruz Hernández JJ, Isla Casado D; SEOM (Spanish Society for Medical Oncology). Pastor Borgoñón M, et al. Clin Transl Oncol. 2010 Nov;12(11):749-52. doi: 10.1007/s12094-010-0590-9. Clin Transl Oncol. 2010. PMID: 20974567
SEOM clinical guidelines for the treatment of head and neck cancer.
Mesía Nin R, Pastor Borgoñón M, Cruz Hernández JJ, Isla Casado D; SEOM (Spanish Society for Medical Oncology). Mesía Nin R, et al. Among authors: pastor borgonon m. Clin Transl Oncol. 2010 Nov;12(11):742-8. doi: 10.1007/s12094-010-0589-2. Clin Transl Oncol. 2010. PMID: 20974566
Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J, Seijas-Tamayo R, Mesía R, Taberna M, Pastor Borgoñón M, Pérez-Ruiz E, Adansa Klain JC, Vázquez Fernández S, Del Barco Morillo E, Lozano A, González Sarmiento R, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). Fernández-Mateos J, et al. Among authors: pastor borgonon m. Oral Oncol. 2016 Dec;63:38-43. doi: 10.1016/j.oraloncology.2016.10.006. Epub 2016 Nov 12. Oral Oncol. 2016. PMID: 27938998 Free article.
Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location.
Seijas-Tamayo R, Fernández-Mateos J, Adansa Klain JC, Mesía R, Pastor Borgoñón M, Pérez-Ruiz E, Vázquez Fernández S, Salvador Coloma C, Rueda Domínguez A, Taberna M, Martínez-Trufero J, Bonfill Abella T, Vázquez Estévez S, Pollán M, Del Barco Morillo E, Cruz-Hernández JJ. Seijas-Tamayo R, et al. Among authors: pastor borgonon m. Clin Transl Oncol. 2016 Nov;18(11):1114-1122. doi: 10.1007/s12094-016-1493-1. Epub 2016 Apr 25. Clin Transl Oncol. 2016. PMID: 27112939
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
Del Barco Morillo E, Mesía R, Adansa Klain JC, Vázquez Fernández S, Martínez-Galán J, Pastor Borgoñon M, González-Rivas C, Caballero Daroqui J, Berrocal A, Martínez-Trufero J, Vera R, Cruz-Hernández JJ; Spanish Head And Neck Cancer Cooperative Group (TTCC). Del Barco Morillo E, et al. Among authors: pastor borgonon m. Oral Oncol. 2016 Nov;62:54-59. doi: 10.1016/j.oraloncology.2016.09.009. Epub 2016 Oct 8. Oral Oncol. 2016. PMID: 27865372 Clinical Trial.
16 results